Posted by Michael Wonder on 25 Feb 2020
FDA approves first generic of ProAir HFA
24 February 2020 - Agency supports development of complex generic drugs to improve competition and access to more affordable medicines.
The U.S. FDA today approved the first generic of ProAir HFA (albuterol/salbutamol sulphate) inhalation aerosol for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older.
